Fedratinib Pill
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasm
Conditions
Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
Trial Timeline
Mar 1, 2022 → Apr 1, 2026
NCT ID
NCT05177211About Fedratinib Pill
Fedratinib Pill is a phase 2 stage product being developed by Bristol Myers Squibb for Myeloproliferative Neoplasm. The current trial status is active. This product is registered under clinical trial identifier NCT05177211. Target conditions include Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05127174 | Phase 1 | Terminated |
| NCT05177211 | Phase 2 | Active |
Competing Products
20 competing products in Myeloproliferative Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 52 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 49 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 49 |
| Ruxolitinib + Lenalidomide + Prednisone | Incyte | Phase 2 | 49 |
| itacitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 74 |
| INCB160058 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 49 |
| INCA035784 | Incyte | Phase 1 | 30 |